Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | RECQL | P46063 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6340344 | 1.00 | KDM6B (0.57) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL22364281 | 0.84 | KDM6B (0.57) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL27315605 | 0.84 | KDM4E (0.59) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL29700186 | 0.84 | KDM6B (0.57) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL7433937 | 0.84 | KDM6B (0.57) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL27285541 | 0.84 | KDM4E (0.59) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL10782448 | 0.84 | KDM6B (0.61) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL3736877 | 0.84 | KDM6B (0.60) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL30915529 | 0.84 | KDM6B (0.60) | KDM6BKDM4EALOX15HIF1AHSD17B10 | |
| SCHEMBL29577557 | 0.84 | KDM6B (0.60) | KDM6BKDM4EALOX15HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| US-8324280-B2 | Treatment of prostate cancer with DDC inhibitor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | claimed |
| US-20100048709-A1 | Treatment of Prostate Cancer with DDC Inhibitor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2010-02-25 | — | — | US | claimed |
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | NAPA THERAPEUTICS LIMITED (IM) | 2025-12-30 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025229624-A2 | NEW CD38 INHIBITORS | NAPA THERAPEUTICS LIMITED (GB) | 2025-11-06 | — | — | WO | disclosed |
| EP-4634194-A1 | SUBSTITUTED DIHYDROPYRROLO [3, 4-D] PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| WO-2008140448-A1 | 5-HTP COMBINATION THERAPY | H. LUNDBECK A/S (DK) | 2008-11-20 | — | — | WO | disclosed |
| US-20070213370-A1 | 5-HTP Combination Therapy | H. LUNDBECK A/S (DK) | 2007-09-13 | — | — | US | disclosed |
| WO-2006073729-A1 | ORAL DISINTEGRATING DOSAGE FORMS | IMPAX LABORATORIES, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20050147670-A1 | Oral disintegrating dosage forms | IMPAX LABORATORIES INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040166159-A1 | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa | IMPAX LABORATORIES, INC. | 2004-08-26 | — | — | US | disclosed |
| EP-0066518-B1 | COMPOUNDS AND METHODS FOR TREATING DEPRESSION | MERRELL DOW FRANCE ET CIE (FR) | 1986-06-11 | — | — | EP | disclosed |
| US-4421767-A | 3-(HYDROXYPHENYL)-2-AMINO-3-BUTENOIC ACID OR DERIVATIVE | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-12-20 | — | — | US | disclosed |
| EP-0066518-A2 | Compounds and methods for treating depression | MERRELL DOW FRANCE ET CIE (FR) | 1982-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | KDM6B 4521/4885KDM4E 4337/4885ALOX15 470/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | KDM6B 1822/4885KDM4E 2619/4885ALOX15 716/4885 |
| US-20070213370-A1 | 5-HTP Combination Therapy | TPH1, HTR1A, HTR4 | KDM6B 3785/4885KDM4E 3118/4885ALOX15 1263/4885 |
| US-12509451-B2 | Heteroaryl amide inhibitors of CD38 | CD38, FCGRT, BCL6 | KDM6B 1682/4885KDM4E 2756/4885ALOX15 1819/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | KDM6B 3027/4885KDM4E 4067/4885ALOX15 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.